What is Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings trades as DNA on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-11-07.
Is DNA in a Closelooknet index?
Not currently — Ginkgo Bioworks Holdings is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-07.
Where does DNA trade against its moving averages?
Ginkgo Bioworks Holdings trades 14.1% above its 50-day and 31.1% above its 200-day moving average (3.2% above its 20-day). As of 2026-11-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.
How does Ginkgo Bioworks Holdings compare with its peers?
Against its peer group (Biotechnology · United States), Ginkgo Bioworks Holdings (DNA) sits 38.0% below its 52-week high, 14.1% above its 50-day average; Moderna Inc (MRNA) is 5.0% below, Exelixis Inc (EXEL) is 5.6% below, Royalty Pharma Plc (RPRX) is 3.5% below, as of 2026-11-06. Put any of them next to DNA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.
How does Ginkgo Bioworks Holdings trade when bond yields rise?
Over the past year Ginkgo Bioworks Holdings had a beta of 1.12 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 86% of US names. On the 10 sessions in which long bonds fell most it moved −0.23% on average, against −0.74% for the S&P 500. As of 2026-11-06; The "How it trades on rate days" block on this page carries the lines.
Where has Closelooknet written about Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings appears in 1 Closelooknet piece as of 2026-11-07, most recently Heresy: Value Investing — Tech-Free, a Flag of Inconvenience (2026-05-07). What Closelooknet said most recently: A portfolio of high-quality slow-growers, dutifully rebalanced, is a portfolio with built-in underperformance DNA .
(Heresy, 2026-05-07). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.
What does Ginkgo Bioworks Holdings do?
Ginkgo Bioworks builds a platform for engineering living cells, selling research services, lab tools and automation systems that other firms use to design organisms for medicines, crops, food and industrial materials. A separate arm, run through its Canopy and Horizon services, gathers genomic data and watches for biological threats for government and other clients. It is based in Boston, Massachusetts. The diary's pack carries no peer group for Ginkgo; the market's own comparison is Twist Bioscience, another company selling synthetic biology and cell-engineering services. (Company snapshot of 2026-09-17.)
Where does Ginkgo Bioworks Holdings sit in the AI build-out?
Ginkgo Bioworks does not sit in Rubin or Halo, our two AI build-out indices; it belongs instead to the healthcare sector, within the biotechnology industry group of our wider universe. Ginkgo Bioworks holds a seat in the Russell 1000 but carries no Rubin or Halo seat and no Closelooknet score. It has been quoted once, in a Heresy piece on value investing that used the letters of its ticker as wordplay rather than as commentary on the company. (Company snapshot of 2026-09-17.)
What has Wall Street done on Ginkgo Bioworks Holdings recently?
The most recent analyst action on Ginkgo Bioworks Holdings on the Closelooknet wire is a initiation by Guggenheim on 2026-08-18 (at Buy). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.
What does this page show?
A live price chart with SMA overlays and drawing tools for DNA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.